Scherpereel A, Mazieres J, Greillier L, et al. Second- or third-line nivolumab (Nivo) versus nivo plus ipilimumab (Ipi) in malignant pleural mesothelioma (MPM) patients: Results of the IFCT-1501 MAPS2 randomized phase II trial. J Clin Oncol. 35, 2017 (suppl; abstr LBA8507).
Darmkanker vaker ontdekt in vroeg stadium, minder operaties en betere overleving
mrt 2024 | Maag-darm-leveroncologie